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scribing to children and adults in a primary care patient population. METHODS: A
retrospective, cross-sectional pharmacoepidemiological study was conducted on
data of a national community pharmacy group in South Africa for 2010. All records
for methylphenidate and/or atomoxetine (ATC Code N06BA) were analysed. Pa-
tients under 18 years were labeled as children, and patients over 18 years as adults.
RESULTS: A total of 22 387 patients (70.05% children and 29.95% adults) received
one or more prescriptions for methylphenidate and/or atomoxetine during 2010. A
total of 60 370 prescriptions were dispensed (75.54% to children and 24.46% to
adults). Most adult patients (43.11%) were between 19 and 29 years of age. Nearly
three-quarters of children (71.84%) were males, compared to only 55.32% of adults.
Children received on average 2.91 prescriptions during the year and adults only
2.20. Methylphenidate accounted for 90.00% of prescriptions to children, and
94.60% to adults. The average sales value for a methylphenidate prescription was
R366.13 for children and R408.42 for adults, compared to the average cost for an
atomoxetine prescription of R582.31 for children and R653.94 for adults. There is no
generic equivalent available for atomoxetine on the South African market. The
average Prescribed Daily Dose (PDD) for methylphenidate was estimated to be 26.27
(SD15.27) mg for children and 41.86 (SD98.57) mg for adults, and the average
PDD for atomoxetine was 38.70 (SD21.45) mg for children and 65.96 (SD118.67)
mg for adults. No seasonal variation was observed for atomoxetine, but methyl-
phenidate prescribing showed peaks and troughs corresponding with the June/July
and December/January holiday periods. CONCLUSIONS: The duration of treatment
and complexity of ADHD treatment is growing, extending into adulthood. Compre-
hensive cost studies into adult ADHD are needed that include quality-of-life and
productivity factors.
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OBJECTIVES: Clinical guidelines recommend monotherapy with antidepressants
for major depression. This study examined prescription patterns and trends as well
as antidepressant polypharmacy among patients with major depression based on
the claims database of health insurance societies between 2008 and 2011 in Japan.
METHODS: Retrospective cohort (N750,000) followed up for four years was used
to identify patients (age  18) with newly diagnosed non-psychotic major depres-
sion. The prescription patterns were examined for antidepressants (first and sec-
ond generation), BZD anxiolytics and hypnotics, sulpiride, and antipsycotics. The
data were analyzed by intent-to-treat approach at month 0, 3, 6 and 12 from the
date of diagnosis. RESULTS: A total of 10,967 patients (male: 5,362, mean age:
3711) with major depression were identified. The proportion of patients pre-
scribed at least one medication was 84% (month 0), 41% (month 3), 35% (month 6)
and 23% (month12). The proportion of patients prescribed antidepressant was 56%
(month 0), 29% (month 3), 24% (month 6) and 16% (month12). BZD anxiolytic was
prescribed to 56% (month 0), 26% (month 3), 22% (month 6) and 14% (month 12) of
the cohort. BZD hypnotics were prescribed to 25% of patients at month 0. Sulpiride
was prescribed to 25%. The proportion of patients with monotherapy of antidepres-
sant was 12% (month 0). Various combinations of polypharmacy were observed.
The most common was combination of antidepressant and BZD anxiolytics (20% at
month 0). Antidepressant with both BDZ anxiolytics and BDZ hypnotics (8% at
month 0) as well as the combination of sulpiride and BZD anxiolytics (6% at month
0) were also common. CONCLUSIONS: The majority of patterns and trends of an-
tidepressant treatment did not follow the guideline recommendation. Various pat-
terns of prescriptions and polypharmacy were observed over time.
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OBJECTIVES: The buprenorphine/naloxone combination has been available in a
film formulation for the treatment of opioid dependence since 2010. A clinical trial
showed that patients preferred the film to tablet formulation. Insurance claims
data were analysed to compare patient persistence with the two formulations.
METHODS: A retrospective cohort analysis was performed using medical insur-
ance claim records extracted from the Invision Datamart database. Previously un-
treated patients who initiated treatment with buprenorphine/naloxone following
the launch of film were classified in two groups according to formulation of initial
prescription. Persistence was defined as the proportion of patients continuing
treatment for at least 6 months, with possible change in formulation. RESULTS:
The film and tablet groups included 1095 and 1048 patients respectively, enrolled
over 6.45 and 8.68 months from initiation of buprenorphine/naloxone on average.
Patient characteristics were similar between groups. In the tablet group, 12.40% of
patients switched to film after 44.5 days on average. Of the patients on film, 2.74%
switched to tablet. Mean prescribed doses were 15.37 and 14.33 mg/day in film and
tablet groups. Among patients enrolled for at least 6 months from buprenorphine/
naloxone initiation, persistence rates were 63.02% in film group vs. 57.97% with
tablet. The time to treatment discontinuation was longer in the film group, with a
hazard ratio of 0.754 (p0.0002) adjusted on age, gender, region, health plan cate-
gory, co-payment proportion, and dose. CONCLUSIONS: Patients started on bu-
prenorphine/naloxone film formulation are more likely to stay on treatment than
patients treated with tablet formulation.
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OBJECTIVES: The discussion on compliance versus non-compliance exercises
many minds in ADHD. Given the potential economic impact, we investigated soci-
etal costs among compliant and non-compliant children with ADHD.METHODS: A
cross-sectional retrospective survey among parents of a child aged 6-18 (members
of the Dutch patient organization) with ADHD was conducted in September 2010.
The TiC-P questionnaire was used to collect data on medical and non-medical
resource use. Reference prices (2010) from the Netherlands were taken as unit
costs. Differences were analysed using Students’ t-tests. Compliance status was
based on parent evaluation and based on pre-defined definitions supported by
expert opinion. RESULTS: This first analysis was based on 473 and 219 children
who were compliant or non-compliant to pharmacological treatment, respectively.
Mean age was 11.2 years, 82.8% were boys. Compliance had a significant influence
on total treatment costs, with total mean monthly costs being €543 (SD € 1141) and
€879 (SD €1368) for compliant and non-compliant children, respectively (p0.001).
The most important cost items were medical consultations (23.4% vs. 26.3%),
coaching and extra support lessons at school (24.0% vs. 18.5%), skills trainings
(18.2% vs. 19.0%), and child day care (13.8% vs. 11.0%). Medication constituted 4.8%
and 2.7% of total costs. Next to compliance, regression analysis showed that co-
morbidity also had a significant influence on total treatment costs (p0.000). In a
regression model in which compliance and comorbidity were independent vari-
ables, both were significant (p0.003 and p0.000, respectively). Mean costs were
€253 and €659 (compliant vs. non-compliant) for children without comorbidity and
€669 and €950 for children with comorbidity. Adding a dummy for
comorbidity*compliance did not show a significant interaction between the two.
CONCLUSIONS: Children compliant to ADHD medication have significant lower
monthly costs compared to non-compliant children. So, effective methods to im-
prove compliance medication in this patient population may be cost-effective.
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OBJECTIVES: Due to varying survey methods and samples, annual direct cost esti-
mates for the care of major depression (MD) in Germany vary between 1264€ and
2577€ per patient in bottom-up cost analyses. To obtain more precise estimates for
costs of MD, we drew a sample from claims data of a statutory health insurance
covering approx. 11% of the German population. By accounting for levels of disease
severity and comorbidities, we (a) provide a stratified cost analysis for MD in Ger-
many and (b) explore potential bias caused by small samples or population selec-
tion criteria. METHODS: We selected a patient cohort aged 18 to 65 and not treated
for depression in the previous 6 months with (a) at least two secured diagnoses of
depression in 2010 and (b) the first depression-related service utilization between
01.01.2010 and 15.02.2010. Depression-related costs for outpatient-care, inpatient-
care, and antidepressants were analyzed for the remaining year 2010 in total and
by provider. Patients were stratified into three disease severity (ds) levels: minor/
unspecified/atypical (ds1), moderate (ds2), and severe (ds3) MD. Furthermore 128
(co)morbidity groups were analyzed. RESULTS: The sample comprised 18,139 pa-
tients with a mean of 887€ in annual direct costs for care of MD. Mean costs by
disease severity and mental comorbidity (mc) were for (ds1): n 11,978 (66%), 623€
(without/with mc 509€/737€); for (ds2): n  4,420 (24%), 1231€ (without/with mc
1056€/1601€); for (ds3): n 1741 (10%), 1838€ (without/with mc 1389€/2483€). While
mental comorbidities significantly explained higher direct costs for depression for
every provider, somatic comorbidities did not. CONCLUSIONS: Our sample re-
vealed (a) a large proportion of patients with low disease severity (ds1) and (b) large
cost differences explained by disease severity and mental comorbidities. Compa-
rable studies reporting higher mean costs for depression may possibly underrep-
resent patients with low disease severity in their sample.
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OBJECTIVES: To develop and apply a longitudinal model adjusting for pre-treat-
ment covariates to examine trajectory patterns of health care costs in patients with
major depressive disorder (MDD) treated with duloxetine. METHODS: Retrospec-
tive health care cost data from Thomson Reuters MarketScan® Database for 10,987
MDD patients, aged 18-64 initiating duloxetine in 2007 at low, standard, or high
doses (60, 60, or 60 mg/day) were used to build a longitudinal model for the
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